BriaCell Therapeutics Corp
Company Profile
Business description
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Contact
235-15th Street
Suite 300, 3rd Floor, Bellevue Centre
West Vancouver
VancouverBCV7T 2X1
CANT: +1 888 485-6340
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 July 2025
Employees
12
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
stocks
Going into earnings, Is Meta stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,939.70 | 13.50 | 0.15% |
| CAC 40 | 7,798.22 | 24.45 | -0.31% |
| DAX 40 | 24,307.80 | 18.29 | 0.08% |
| Dow JONES (US) | 44,323.07 | 19.12 | -0.04% |
| FTSE 100 | 9,012.99 | 20.87 | 0.23% |
| HKSE | 24,994.14 | 168.48 | 0.68% |
| NASDAQ | 20,974.18 | 78.52 | 0.38% |
| Nikkei 225 | 40,003.01 | 183.90 | 0.46% |
| NZX 50 Index | 12,852.62 | 108.89 | -0.84% |
| S&P 500 | 6,305.60 | 8.81 | 0.14% |
| S&P/ASX 200 | 8,679.80 | 11.60 | 0.13% |
| SSE Composite Index | 3,559.79 | 25.31 | 0.72% |